Drug Trial Radar · NCT02522325
Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 2015
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- William StoopsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Aug 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.
Conditions
- Cocaine Use Disorder
Interventions
PhendimetrazineDrug
Phendimetrazine will be administered in divided doses twice daily.
CocaineDrug
Intranasal cocaine will be administered during experimental sessions.
PlaceboDrug
Placebo capsules will contain only cornstarch.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Times Cocaine Was Selected in the Presence of a Monetary Reward AlternativeTime frame: After at least seven days of maintenance placebo or target phendimetrazine dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky Department of Behavioral Science
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.